Global Acute Heart Failure (AHF) Therapeutics Strategic Business Opportunity Outlook 2018-2022 - Novel Treatments Offer a Ray of Hope - ResearchAndMarkets.com

DUBLIN--()--The "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Next Generation Sequencers in US$ Thousand.

The Global market is additionally analyzed by the following End-Use Segments:

  • Pharmaceutical/Biotech
  • Industrial
  • Government/Academia

The report profiles 93 companies including many key and niche players such as:

  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Cardiorentis AG (Switzerland)
  • CVie Therapeutics Limited (Taiwan)
  • Cytokinetics, Inc. (USA)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • Orion Corporation (Finland)
  • PhaseBio Pharmaceuticals, Inc. (USA)

Key Topics Covered

1. Industry Overview

2. Market Drivers, Trends & Issues

  • Conventional Therapies Leave Considerable Unmet Needs
  • Novel Treatments Offer a Ray of Hope
  • Key AHF Therapeutics in the Pipeline
  • Serelaxin Nears Trial Readout form RELAX-AHF-2
  • Ularitide - A Novel Drug in Development for AHF
  • The Litany of Drug Failures Expands, Emphasis on Prevention Grows
  • Other Promising Drugs under Development
  • Research Findings
  • Kidney Dysfunction
  • Predictor of Acute Heart failure
  • Genetic Influence on Heart Disease among African Americans
  • Higher Body Mass Index - A Key Risk Factor for AHF
  • Supplemental Oxygen Therapy May not be for All Cases of AHF
  • Macro Growth Drivers
  • Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
  • CVD: Fast Facts
  • Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics

3. Treatment of Acute Heart Failure (AHF)

4. Acute Heart Failure

5. Recent Industry Activity

6. Focus on Select Players

7. Global Market Perspective

Total Companies Profiled: 34 (including Divisions/Subsidiaries 35)

  • The United States (18)
  • Japan (2)
  • Europe (10)
    • Germany (2)
    • The United Kingdom (2)
    • Italy (1)
    • Rest of Europe (5)
  • Asia-Pacific (Excluding Japan) (5)

For more information about this report visit https://www.researchandmarkets.com/research/j95wwt/global_acute?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs, Cardiology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs, Cardiology